The news. The narrative. The timeline.
Bureau: Chicago
The FDA sent warning letters to 30 telehealth companies over illegal GLP-1 marketing while Novo Nordisk and Hims settled — a regulatory landscape still being written in real time.
Twelve days after a landmark BMJ study, the medical community is reckoning with what the 22% cardiovascular risk figure actually demands of patients and clinicians.
FDA issued warning letters to 30 telehealth companies in February for misleading GLP-1 claims, part of a broader enforcement push on compounded weight-loss drugs.
As GLP-1 adoption scales toward mass market, researchers document downstream effects on body image, dating dynamics, and workplace interactions.